<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973112</url>
  </required_header>
  <id_info>
    <org_study_id>HLX10-008-HCC201</org_study_id>
    <nct_id>NCT03973112</nct_id>
  </id_info>
  <brief_title>A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients</brief_title>
  <official_title>A Single-arm, Open, Multicenter, Phase II Clinical Study Evaluating the Use of HLX10 (Recombinant Anti-pd-1 Humanized Monoclonal Antibody Injection) in Combination With HLX04 (Recombinant Anti-vegf Humanized Monoclonal Antibody Injection) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Henlius Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Henlius Biotech</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a single-arm, open, multicenter phase II clinical study.Subjects can only enter&#xD;
      this study after they meet the inclusion and exclusion criteria.Into subjects will accept&#xD;
      HLX10 + HLX04 intravenous infusion, every two weeks, lose treatment until clinical benefit,&#xD;
      toxicity, the subjects of the resistance or the doctor decided to suspend the treatment,&#xD;
      tested subjects death revocation of informed consent, subjects, subjects of pregnancy, not to&#xD;
      plan or program requirement from, or management reasons, treatment for up to 2 years&#xD;
      (before).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate(assessed by independent radiological review</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Objective response rate (assessed by the investigators based on the RECISTv1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month OS rate</measure>
    <time_frame>from the date of first dose unitl the date of 12-month</time_frame>
    <description>12-month overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>from the date of first dose unitl the date of death from any cause，assessed up to 2 years</time_frame>
    <description>Overall survival (OS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-month PFS rate</measure>
    <time_frame>the proportion of subjects who have time interval over 12 months between the first dose and disease progression or death</time_frame>
    <description>12-month progression-free survival (PFS) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years</time_frame>
    <description>Progression-free survival (assessed by independent radiological review</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>from the first dose until firstly confirmed and recorded disease progression or death (whichever occurs earlier),assessed up to 2 years</time_frame>
    <description>Progression-free survival (assessed by the investigators based on RECIST v1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>from the date when CR or PR (whichever recorded earlier) is firstly achieved until the date when disease progression or death is firstly recorded (whichever occurs earlier),assessed up to 2 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HLX10+HLX04</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HLX10+HLX04</intervention_name>
    <description>HLX10 developed by our company is sterile intravenous injection, with specification of 100 mg/10 mL/bottle. The main ingredient is 10.0 mg/mL of recombinant humanized anti-PD-1 monoclonal antibody. HLX04 is an anti-tumor angiogenesis drug, which is a biosimilar drug bevacizumab designed and developed by Shanghai fuhonghanlin biotechnology co., ltd. based on the protein sequence of Avastin® by Roche pharmaceutical company.</description>
    <arm_group_label>HLX10+HLX04</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet all of the following criteria are allowed to be enrolled into this&#xD;
             study:&#xD;
&#xD;
               -  Volunteer to participate in clinical research;To fully understand and understand&#xD;
                  this study and to sign the Informed Consent Form (ICF);Willing to follow and able&#xD;
                  to complete all test procedures.&#xD;
&#xD;
               -  The age of signing ICF is ≥ 18 years old and ≤ 75 years old.&#xD;
&#xD;
               -  Subjects with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology&#xD;
                  or cytology, or clinically diagnosed as meeting the criteria for hepatocellular&#xD;
                  carcinoma of the American association of liver diseases (AASLD).&#xD;
&#xD;
               -  arm A、B Failure or intolerable toxicity after at least one standard first-line&#xD;
                  systemic treatment for advanced hepatocellular carcinoma.Previous standard&#xD;
                  first-line systemic therapy included sorafenib, renvastinib and oxaliplatin based&#xD;
                  chemotherapy.&#xD;
&#xD;
               -  arm D never used systemic treatment&#xD;
&#xD;
               -  Barcelona Clinic Liver Cancer (BCLC) (appendix I) stage C;BCLC stage B patients&#xD;
                  who are not suitable for locoregional therapy may also be enrolled.&#xD;
&#xD;
               -  At least one measurable lesion assessed by IRRC according to RECIST v1.1&#xD;
                  (appendix ii) has not been treated locally for this lesion (e.g., radiotherapy,&#xD;
                  radiofrequency ablation, TACE, ultrasound focusing knife, etc.).&#xD;
&#xD;
               -  The end of previous systematic treatment must be ≥ 2 weeks after the first&#xD;
                  medication in this study, and the treatment-related AE should be restored to the&#xD;
                  level of ci -CTCAE ≤ 1 (except hair loss).&#xD;
&#xD;
               -  Child-pugh liver function rating within 7 days before the first administration of&#xD;
                  the study drug (appendix iii) : grade A and good grade B (≤ 7 points).&#xD;
&#xD;
               -  The ECOG physical performance score (appendix iv) for the 7 days prior to the&#xD;
                  first administration of the study drug was 0 or 1.&#xD;
&#xD;
               -  Expected survival ≥ 12 weeks.&#xD;
&#xD;
               -  Subjects of HBsAg (-) and HBcAb (-) were admitted into the group;If HBsAg (+) or&#xD;
                  HBcAb (+), hbv-dna must be ≤ 500 IU/mL to be included in the group, and those&#xD;
                  with elevated hbv-dna must agree to receive nucleoside anti-hepatitis b virus&#xD;
                  treatment.Subjects with negative HCV antibody (-) or hcv-rna were admitted.If&#xD;
                  hcv-rna is positive, subjects must have ALT and AST ≤ 3×ULN to be&#xD;
                  enrolled.Subjects with co-infection of hepatitis b and c should be excluded.&#xD;
&#xD;
               -  Major organs function normally and meet the following criteria (no blood&#xD;
                  transfusion, albumin, recombinant human thrombogenin or colony stimulating factor&#xD;
                  (CSF) treatment was received within 14 days prior to the first administration of&#xD;
                  this study)&#xD;
&#xD;
               -  Female subjects must meet:&#xD;
&#xD;
        Menopause (defined as having not had menstruation for at least 1 year and having no other&#xD;
        known cause other than menopause), or Surgical sterilization (removal of ovaries and/or&#xD;
        uterus), or have fertility, but must meet: serum pregnancy test must be negative within 7&#xD;
        days prior to first administration, and , agreed to the annual failure rate &lt; 1% of&#xD;
        contraception or abstinence (avoid heterosexual intercourse) (from signed informed consent&#xD;
        to test drugs at the end of the time at least 120 days) after the treatment (annual failure&#xD;
        rate &lt; 1% of contraceptive methods including bilateral tubal ligation, male sterilization&#xD;
        techniques, the correct use can inhibit ovulation hormonal contracepties, releasing hormone&#xD;
        of intrauterine contraceptive device and copper intrauterine contraceptive device), and do&#xD;
        not breastfeed.&#xD;
&#xD;
        • Male subjects must be satisfied: agree with abstinence (avoid heterosexual intercourse)&#xD;
        or contraceptive measures, the rules are as follows: spouse or partner has been pregnant&#xD;
        for childbearing age women, male subjects must be at the end of the experiment during drug&#xD;
        dosage and drug time at least 120 days after the treatment, keep abstinence or use condoms&#xD;
        for birth control in order to prevent drug exposure in the embryo.The duration of the&#xD;
        clinical study and the reliability of the subjects' preferences and daily lifestyle&#xD;
        measures of abstinence should be considered.Regular abstinence (e.g., calender days,&#xD;
        ovulation, basal body temperature, or post-ovulation methods) and ejaculation are not&#xD;
        acceptable methods of contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet any of the following criteria are not allowed to be enrolled in this&#xD;
             study:&#xD;
&#xD;
               -  Hepatobiliary duct cell carcinoma, mixed cell carcinoma, or fibroblastic layer&#xD;
                  cell carcinoma are known.&#xD;
&#xD;
               -  Other active malignancies within 5 years prior to the first administration of the&#xD;
                  study drug.Curable localized tumors, such as basal cell carcinoma of the skin,&#xD;
                  squamous cell carcinoma of the skin, superficial bladder carcinoma, carcinoma in&#xD;
                  situ of the prostate, cervical carcinoma in situ, and carcinoma in situ of the&#xD;
                  breast, can be included in the group.&#xD;
&#xD;
               -  People who are ready to undergo or have received organ or bone marrow&#xD;
                  transplants.&#xD;
&#xD;
               -  After appropriate intervention, uncontrollable pleural effusion, pericardial&#xD;
                  effusion or ascites still need to be drained frequently (once a month or more&#xD;
                  frequently).&#xD;
&#xD;
               -  Symptomatic, untreated, or progressive central nervous system (CNS) or meningeal&#xD;
                  metastasis.Asymptomatic subjects treated for CNS lesions can be enrolled if all&#xD;
                  of the following criteria are met:&#xD;
&#xD;
                    1. in addition to CNS, there must be lesions that can be measured according to&#xD;
                       RECIST v1.1;&#xD;
&#xD;
                    2. the patient had no history of intracranial or spinal bleeding;&#xD;
&#xD;
                    3. metastatic lesions were limited to cerebellum or supratentorial areas (i.e.,&#xD;
                       no mesencephalon, pons, medulla or spinal cord metastatic lesions);&#xD;
&#xD;
                    4. there was no evidence of progress between the completion of CNS oriented&#xD;
                       therapy and the start of research and treatment;&#xD;
&#xD;
                    5. the patients did not receive stereotactic radiotherapy within 7 days before&#xD;
                       the study treatment, did not receive whole-brain radiotherapy within 14 days&#xD;
                       before the study treatment, and did not receive neurosurgical resection&#xD;
                       within 28 days before the study treatment;&#xD;
&#xD;
                    6. patients have no need for continuous use of glucocorticoids in the treatment&#xD;
                       of CNS diseases.Stable doses of anticonvulsant therapy are permitted;&#xD;
&#xD;
                    7. asymptomatic patients with newly detected CNS metastases during screening&#xD;
                       are eligible to participate in the study after receiving radiotherapy or&#xD;
                       surgical treatment, and there is no need to repeat screening of brain scan&#xD;
                       results.&#xD;
&#xD;
               -  Cerebrovascular accident, myocardial infarction, unstable angina pectoris and&#xD;
                  poorly controlled arrhythmia occurred within half a year (including QTc interval&#xD;
                  ≥ 450 ms for men and ≥ 470 ms for women) (QTc interval was calculated by&#xD;
                  Fridericia formula).&#xD;
&#xD;
               -  According to the New York heart association (NYHA) standard (appendix 5) levels Ⅲ&#xD;
                  or Ⅳ cardiac insufficiency or heart colour to exceed examination: LVEF, left&#xD;
                  ventricular ejection fraction &lt; 50%.&#xD;
&#xD;
               -  A history of hepatic encephalopathy.&#xD;
&#xD;
               -  According to the images, portal vein invasion, inferior vena cava or cardiac&#xD;
                  involvement of HCC main portal branch (Vp4) were present.Patients with cancer&#xD;
                  thrombus in main portal vein but smooth blood flow in contralateral branch can be&#xD;
                  enrolled.&#xD;
&#xD;
               -  Involving major airways, vessels, or large mediastinal mass located centrally (&lt;&#xD;
                  30 mm from the crest).&#xD;
&#xD;
               -  Human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
               -  Active tuberculosis.&#xD;
&#xD;
               -  Patients with previous and current cases of interstitial pneumonia,&#xD;
                  pneumoconiosis, radioactive pneumonia, drug-related pneumonia, and severe&#xD;
                  impairment of lung function that may interfere with the detection and management&#xD;
                  of suspected drug-related lung toxicity.&#xD;
&#xD;
               -  Known activity or autoimmune disease or history.&#xD;
&#xD;
               -  The study drug was treated with live attenuated vaccine within 28 days prior to&#xD;
                  its first administration.&#xD;
&#xD;
               -  Subjects requiring systemic treatment with corticosteroids (&gt; 10 mg/ day or&#xD;
                  equivalent dose of prednisone) or other immunosuppressants within 14 days prior&#xD;
                  to or during the study.In the absence of active autoimmune disease, the&#xD;
                  inhalation or topical use of steroids, or adrenal hormone replacement at doses&#xD;
                  less than 10 mg/ day of prednisone efficacy, is permitted.&#xD;
&#xD;
               -  Within 14 days prior to the first administration of the study drug, any active&#xD;
                  infection requiring systematic anti-infective treatment occurs.&#xD;
&#xD;
               -  Major surgery was performed within 28 days prior to the first administration of&#xD;
                  the study drug. Major surgery in this study was defined as the minimum recovery&#xD;
                  time of 3 weeks after surgery before the surgery treated in this study could be&#xD;
                  performed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ethics committee of zhongshan hospital affiliated to fudan university</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 2, 2019</study_first_submitted>
  <study_first_submitted_qc>June 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

